Street today. Two major retail names are getting together. It was endo that ended up being the biggest acquirer. With an agreement to buy par pharmaceuticals. The deal will make Endo International an even bigger player in the fast changing and fast consolidating generic drug sector. Shares of endofell more than 5 . Bertha coombs has more on the deal. Repor drug makers that produce generic drugs are attracting big bucks. Endopaying 8 billion for par pharmaceutical 13e6kly in generics this will position us as a top generics player in the u. S. Endos shares fell some analysts citing costs, par pharma was taken for just 2 billion in 2012. Pfizer recently bought hospira for 16 billion, while teva has been 40 billion dollar for mylon, which is 40 billion for perilow. Its a nice environment to do m a. Companies are looking to fill their pipelines of products. New specialty drugs can command high prices some generic drug prices have skyrocketed. Govern data shows prices for generic cholesterol
Street today. Two major retail names are getting together. It was endo that ended up being the biggest acquirer. With an agreement to buy par pharmaceuticals. The deal will make Endo International an even bigger player in the fast changing and fast consolidating generic drug sector. Shares of endofell more than 5 . Bertha coombs has more on the deal. Repor drug makers that produce generic drugs are attracting big bucks. Endopaying 8 billion for par pharmaceutical 13e6kly in generics this will position us as a top generics player in the u. S. Endos shares fell some analysts citing costs, par pharma was taken for just 2 billion in 2012. Pfizer recently bought hospira for 16 billion, while teva has been 40 billion dollar for mylon, which is 40 billion for perilow. Its a nice environment to do m a. Companies are looking to fill their pipelines of products. New specialty drugs can command high prices some generic drug prices have skyrocketed. Govern data shows prices for generic cholesterol
Street today. Two major retail names are getting together. It was endo that ended up being the biggest acquirer. With an agreement to buy par pharmaceuticals. The deal will make Endo International an even bigger player in the fast changing and fast consolidating generic drug sector. Shares of endofell more than 5 . Bertha coombs has more on the deal. Repor drug makers that produce generic drugs are attracting big bucks. Endopaying 8 billion for par pharmaceutical 13e6kly in generics this will position us as a top generics player in the u. S. Endos shares fell some analysts citing costs, par pharma was taken for just 2 billion in 2012. Pfizer recently bought hospira for 16 billion, while teva has been 40 billion dollar for mylon, which is 40 billion for perilow. Its a nice environment to do m a. Companies are looking to fill their pipelines of products. New specialty drugs can command high prices some generic drug prices have skyrocketed. Govern data shows prices for generic cholesterol